Stephenson Harwood advises on $25 million funding in ViaNautis Bio

Stephenson Harwood LLP has advised UCB Ventures, BGF and 4Bio Capital, who led the over-subscribed Series A funding round of $25million in ViaNautis Bio.

ViaNautis, formerly known as SomaServe, has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.

The raise was led by UCB Ventures, BGF and 4Bio Capital, and additional participation was provided by the Cystic Fibrosis Foundation, Eli Lilly and Company, as well as existing investors including Origin Capital, Meltwind and O2H. The proceeds from the round will be used to fuel the rapid development of products using the polyNaut® platform, expand the scientific and management teams and establish industry-leading laboratory facilities. ViaNautis' proprietary drug delivery platform is designed to deliver genetic therapeutic payloads to the specific site of action.

The Stephenson Harwood team comprised of corporate partner Anthony Clare and corporate associates Michelle Gomes and Yuki Yue, with further assistance provided by IP partner Naomi Leach and associate Ainsleigh Stone.

Related Expertise

Life Sciences A to Z - R is for Rare Diseases in the UK: An Overview of the Regulatory and Policy Landscape

Life Sciences & Healthcare

Insights Orange Mushroom Gills Adobestock 137390679 OVERLAY

Partner Paul Inman joins Stephenson Harwood

Life Sciences & Healthcare

Lifesciences Istock 1181631890 Test Tube Dropper Droplet

Media coverage: Private clinics and hospitals in difficulty - what risks, good practices, and opportunities?

Restructuring & Insolvency

Stephenson Harwood advises KIMSHEALTH on True North exit and Shari’ah-compliant financing

Private Equity

Stephenson Harwood advises on triple acquisition deal for Vulcan Two Group

Life Sciences & Healthcare

Life Sciences A to Z - Q is for Quantum Computing: Opportunities and challenges for life sciences innovation

Life Sciences & Healthcare

Stephenson Harwood advises on $25 million funding in ViaNautis Bio

Share Article

Related Expertise

Contributors

Michelle Gomes

Naomi Leach

Related Articles

Life Sciences A to Z - R is for Rare Diseases in the UK: An Overview of the Regulatory and Policy Landscape

Partner Paul Inman joins Stephenson Harwood

Media coverage: Private clinics and hospitals in difficulty - what risks, good practices, and opportunities?

Stephenson Harwood advises KIMSHEALTH on True North exit and Shari’ah-compliant financing

Stephenson Harwood advises on triple acquisition deal for Vulcan Two Group

Life Sciences A to Z - Q is for Quantum Computing: Opportunities and challenges for life sciences innovation

Stephenson Harwood successfully represent GPI SpA in procurement challenge

Stephenson Harwood Advises on sale of Symprove

Stephenson Harwood advises Patchs Health on sale to OneAdvanced

Life Sciences A-Z - P is for Privilege